The price Americans pay for medicine has gotten horribly out of control. Here’s how to fix it.
The United States is the only wealthy country where a routine trip to the pharmacy can trigger financial panic. List prices for brand‑name medicines are often several times higher than in peer nations. Even many generics swing wildly in price or face shortages. Patients ration insulin, skip refills, and land in emergency rooms because the cash price of a decades‑old drug topped their budget that month. Employers watch pharmacy benefit costs rise fast enough to crowd out wages. Taxpayers pick up the rest.
How did we get here—and how do we get out? The short answer is that we built a market that rewards high list prices, shields monopolies from competition longer than necessary, and pushes costs onto the people who can least absorb them. The fix is not a single silver bullet but a package of changes that realign incentives with value, invite more competition, and protect patients at the counter.
Why U.S. drug prices are so high
– Market power by design. When a new drug launches, it often enjoys years without meaningful competition. That’s the point of patents and exclusivity—but companies can extend that power through tactics like patent “thickets,” minor reformulations, and “pay‑for‑delay” deals that postpone generic entry. The result can be years of monopoly pricing even after the science has become well understood.
– Fragmented buyers, weak leverage. In most countries, a national system negotiates drug prices and can say no when the price doesn’t match the benefit. The U.S. splinters purchasing across thousands of plans. Until recently, Medicare couldn’t even negotiate on many drugs. Fragmentation raises administrative costs and erodes negotiating leverage.
– Misaligned middlemen incentives. Pharmacy benefit managers (PBMs) negotiate rebates from drugmakers in exchange for favorable placement on plan formularies. But many PBM fees are tied to list prices. That can favor higher list prices with bigger rebates rather than lower net prices overall, and the savings don’t always reach the patient at the counter.
– Bottlenecks for generics and biosimilars. Generics usually bring prices down sharply, but they can be kept off the market by litigation, supply chain fragility, scarce manufacturing capacity, or tactics that block competitors’ access to samples. Biosimilars—competitors to complex biologic drugs—face additional scientific and regulatory hurdles and slow uptake because of contracting practices.
– Benefit designs that punish the sick. High deductibles and coinsurance based on list prices mean patients who need medicines pay the most and pay it up front, even when their plan is paying a much lower net price behind the scenes. For a person with diabetes, that can turn a lifesaving therapy into a monthly budget crisis.
– Marketing and me‑too medicines. Promotion can shift demand toward newer, pricier drugs even when older options work well, and manufacturers often launch “me‑too” products that are clinically similar but carry premium prices.
What’s changed—and what hasn’t
Recent reforms have started to chip away at the problem. Medicare is beginning to negotiate prices for a limited number of high‑spend drugs, penalize price hikes above inflation, and cap out‑of‑pocket costs for seniors, including a monthly cap for insulin. Several states have moved to curb PBM spread pricing and require more transparency.
But the core distortions remain. Negotiation is limited in scope and doesn’t apply to most private coverage. Patent gaming and anticompetitive contracting persist. Patients in employer plans still pay coinsurance on inflated list prices. And breakthrough therapies are arriving with six‑figure price tags that the current system is ill‑equipped to assess or pay for sustainably.
A practical blueprint to fix U.S. drug pricing
1) Negotiate smarter and at scale
– Expand federal negotiating authority beyond a handful of drugs and beyond Medicare where feasible. Use clear rules that tie payment to clinical value and unmet need, not just market power.
– Apply inflation penalties across public programs and, where possible, the commercial market to discourage year‑over‑year list price hikes untethered to added value.
– Allow therapeutic reference pricing within formularies: pay similar prices for drugs that deliver similar outcomes.
2) End patent and exclusivity abuses
– Tighten standards to curb patent thickets and evergreening that don’t reflect real therapeutic advances.
– Ban pay‑for‑delay and other settlement tactics that postpone generic or biosimilar entry.
– Make it easier to challenge weak patents quickly and cheaply, and prioritize the review of challenges with the largest potential savings.
3) Supercharge competition from generics and biosimilars
– Fully fund the FDA to speed review of complex generics and biosimilars, and publish clear interchangeability guidance to boost uptake when safe and appropriate.
– Stop tactics that block competitors’ access to samples needed for testing, and streamline risk‑management programs that have been misused to stall rivals.
– Encourage competitive, transparent contracting that doesn’t lock in incumbents or penalize switching to lower‑cost options.
4) Realign PBM incentives with patient value
– Require pass‑through of all manufacturer rebates and fees to plan sponsors, with point‑of‑sale application so patients benefit at the counter.
– Ban spread pricing and mandate simple, auditable compensation models for PBMs that are delinked from list prices.
– Impose a fiduciary duty to purchasers and prohibit contract clauses that gag pharmacists or disadvantage lower‑cost drugs.
5) Cap and smooth out‑of‑pocket costs
– Set reasonable annual caps on patient out‑of‑pocket spending across all types of coverage, not just Medicare, and allow patients to spread costs evenly through the year (smoothing).
– Base coinsurance on net prices, not inflated list prices, so patients share in the actual discount their plan receives.
– Keep and expand targeted caps for essential chronic medications like insulin.
6) Tie payment to real‑world outcomes
– Use outcomes‑based contracts for high‑cost specialty drugs, where the price a plan pays depends on how well the therapy works in practice.
– Pilot “subscription” models for curative treatments—states have used this approach to expand access to hepatitis C cures while capping total spend.
– Build national infrastructure for real‑world evidence so value assessments reflect diverse patient populations and long‑term benefits and risks.
7) Create public options for essential medicines
– Expand nonprofit and public‑private manufacturing of off‑patent, high‑importance generics to stabilize supply and discipline prices when markets fail.
– Establish strategic reserves for key active pharmaceutical ingredients to prevent shortages that fuel price spikes.
8) Reward true innovation while curbing waste
– Use prize funds, advanced market commitments, or time‑limited exclusivity extensions to reward breakthroughs that address major unmet needs, in exchange for lower prices or rapid genericization after the reward period.
– Increase transparency around launch pricing rationales and R&D subsidies, while avoiding blunt measures that could chill high‑value research.
9) Guardrails for publicly funded science
– Enforce “reasonable pricing” expectations when taxpayer‑funded discoveries become products, and use existing march‑in authority judiciously when access is unreasonably restricted.
– Strengthen licensing terms to ensure public return on public investment without deterring partnerships that bring discoveries to market.
10) Enable safe importation and parallel competition
– Allow well‑regulated importation from trusted countries for drugs with long‑standing safety profiles, with strong tracking to prevent counterfeits.
– Use the credible threat of importation to discipline domestic launch prices when markets fail.
Addressing the innovation argument
You’ll hear that any strong push on prices will kill the golden goose of biomedical innovation. It’s a real risk if reform is blunt and indiscriminate. But today’s system overspends on low‑value drugs, rewards minor tweaks, and pays vastly different prices for the same product depending on who’s negotiating. Other wealthy countries pay less for medicines and still see new drugs launched; U.S. companies remain among the most profitable in any industry. The path forward is to pay more for genuine breakthroughs that change the standard of care—and much less for “me‑too” drugs and aging monopolies.
What success looks like
– Patients fill prescriptions without fear of financial harm. Rationing vanishes; adherence rises.
– Employers and families see premium growth moderate as waste drains out of the system.
– Generic and biosimilar markets are vibrant, with predictable pricing and fewer shortages.
– Launch prices better reflect clinical value, with faster price declines as competition arrives.
– The U.S. still leads in biomedical discovery, but dollars flow toward truly novel science.
How to get there, practically
– Start where consensus exists: ban spread pricing; require point‑of‑sale rebates; enforce anti‑evergreening rules; prosecute anticompetitive contracting; accelerate complex generics and biosimilars.
– Build on momentum: expand Medicare negotiation gradually, guided by transparent value frameworks; extend inflation caps; harmonize benefit designs to protect patients in employer plans.
– Pilot, measure, scale: outcomes‑based contracts, subscription models, nonprofit manufacturing. Publish results, iterate, and expand what works.
– Align agencies: FDA, FTC, CMS, and DOJ should coordinate on competition, safety, and payment reform so one fix doesn’t create another bottleneck.
The status quo is not inevitable. High drug prices in America are the predictable result of policy choices. Better choices—rooted in value, competition, and patient protection—can deliver the medicines people need at prices they can afford, without dimming the lights on innovation. The stakes are measured in lives, livelihoods, and trust. It’s time to rebuild a market that rewards cures, not clever pricing.
